Search
for
Sort by
Research 31–60 of 1000+
- Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
- Efficacy and safety of janus kinase inhibitors in the treatment of alopecia areata in children
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Association of Janus kinase inhibitors with reduced depression in alopecia areata
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Tofacitinib for the treatment of lichen planopilaris: A case series
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Treatment of severe alopecia areata with baricitinib
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Ruxolitinib found to cause eyelash growth: a case report
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata